Announcement by the President of the Nation, Alberto Fernández, and the Minister of Health of the Nation, Doctor Ginés González García, regarding the production, in our country, of the Oxford vaccine against the new coronavirus, COVID-19, from Olivos.

Argentina Alberto Fernández · President of Argentina

12 August 2020 · Announcement regarding production of the Oxford COVID-19 vaccine in Argentina · Olivos

Context
Fernández announced Argentina's role in producing the Oxford-AstraZeneca COVID-19 vaccine for Latin America, alongside Mexico, from the Olivos presidential residence on August 12, 2020.
Main themes
Oxford-AstraZeneca COVID-19 vaccine, vaccine production agreement, Argentina and Mexico regional manufacturing, Latin American vaccine access, mAbxience laboratory, Slim Foundation funding, vaccine pricing and equity, public-private partnership, COVID-19 pandemic response, vaccine clinical trial progress, national pharmaceutical capacity
Duration
~29 min
81st percentile
Words
3,448
81st percentile
Sentences
103
64th percentile
Readability
40
36th percentile
Grade
16.0
83rd percentile
Syntax
3.35
86th percentile
Vocabulary
2.04
16th percentile

Translated from Spanish

Content
Actors
Style

The broad sphere of national life a sentence belongs to. Every sentence has an Arena, so it is the denominator the other indices are read against.

Other
  • Social 56%55%
  • Economic 25%25%
  • Ceremonial 11%11%
  • Geopolitical 7%7%
  • Technological 1%1%
  • Environmental 0%0%
  • Institutional 0%0%
  • Not in focus 1%

103 sentences in 25 paragraphs

PRESIDENT.- Good evening everyone, we are here to share something that we have been working on with the Minister of Health for some time now. You know that one of the concerns we have always had is to ensure that when the vaccine is ready, Argentina does not have to wait and can access it as soon as possible.

The laboratory AstraZeneca, which has been established in Argentina for many years, has signed an agreement with the University of Oxford, as you all know, for the development of a candidate vaccine against COVID-19, which is currently in phase 3 of development. The laboratory has signed an agreement with the Slim Foundation to produce between 150 and 250 million vaccines for Latin America, with the exception of Brazil, which will be available in the first half of 2021 and will be distributed equitably among the countries that request it and at the request of the governments of each of those countries.

The Latin American production will be carried out by Argentina and Mexico, and this will allow timely and sufficient access to the potential vaccine for all countries in the region.

This agreement allows Latin America, and Argentina in particular, to access the vaccine 6 to 12 months earlier than we would have been able to acquire it without this agreement. For Latin America, Argentina and Mexico will be responsible for the production chain; I hope to speak shortly with President José López Obrador, which is a great joy for us.

In Argentina, AstraZeneca has chosen the mAbxience Laboratory, which will be responsible for producing the active substance of the vaccine. This is a tremendous challenge for the national industry and for us, it is also a recognition of the quality of Argentine laboratories, particularly mAbxience. Mexico will be responsible for packaging the vaccine and completing the production process, and finally, all production will be distributed equitably, at the request of the Latin American governments.

I want to express my satisfaction with this because it places Argentina in a position of tranquility, basically, to be able to count on the vaccine in a timely manner when we need it and in sufficient quantity to cover the immediate demand we have to meet.

I want to particularly emphasize the work of the AstraZeneca laboratory, which, as you know, is a British-Swedish laboratory that has been in Argentina for many years and has made an agreement with the University of Oxford to develop this vaccine, but the contribution made by the Slim Foundation has allowed us to access this vaccine at much more than reasonable prices, and that is very important; the price of the vaccine is estimated to be between 3 and 4 dollars per dose, which is very significant for Latin America because it allows all our countries to access it.

I think it is very good news about how the private sector and the public sector can work together, and I think it is great news that the Slim Foundation has financed a large part of this production so that all of Latin America can access this product. I also think it is great news that Mexico and Argentina are the reference points for vaccine production and that we can thus bring a solution to the continent, and we hope that we can start the production process as soon as possible. I will now give the floor to the Minister of Health, my dear friend Ginés, to provide more technical details.

GONZÁLEZ GARCÍA.- Thank you, Mr. President. We are proud and obviously happy because we are trying to ensure, as our government proposed from the very beginning, access to the vaccine, and one way to ensure access is to have a reasonable price. In that sense, we are also proud because it is not easy to produce the raw material for a vaccine of this complexity, and happily, having national production capacity fills us with pride. Furthermore, as the President mentioned, while the vaccine is completing its cycle, which is not finished yet, it is clear that this vaccine is leading the world in terms of its clinical phase. What do I mean by this? I mean that, for example, on July 20, there were already publications indicating that the initial studies being conducted in various countries show an extraordinary capacity for immunity with just one dose of the vaccine. Ninety-one percent of the patients who received the vaccine and participated in the clinical trial had immunity, and with two doses, it was 100 percent, so we are clearly on a path not only because of its timeliness, as it is the most advanced, but also because of its effectiveness.

Along with that, we must also tell you that this is neither the only negotiation nor perhaps the only alternative because we continue to work; you know that our country is conducting a clinical trial with another provider, and it is also true that we are continuing discussions with other providers to ensure, first, obviously which is the best or most effective, and second, when we can have it available to immunize Argentines. But it is also true that having local production capacity is not only a very good news for all of Latin America, along with Mexico, as the President said, but also a guarantee of access to the vaccine in a timely manner. So we are really very happy; obviously, something very important is being done, which is that before the studies of the experimental phase are completed, production is starting. That is what the President meant when he said it is at risk; you realize that if the vaccine were not useful, everything invested in that manufacturing would be lost. Therefore, this is a very important phenomenon, and of course, the fact that it is also being done in Argentina— as the President said— ensures at least a long time compared to what some other providers were expected to deliver. Moreover, the idea that these investigations are led by countries in the northern hemisphere could potentially put us at some risk regarding access; we believe that in this way we are ensuring or at least making many decisions that mean this, and of course, we thank not only the laboratory but also all the capacity that Argentina has to be entrusted with nothing less than producing the raw material for such an important vaccine. So with that, I think we have clarified, and of course, we all want it as soon as possible, and we will all do everything we can to have it as soon as possible.

PRESIDENT.- Thank you, Ginés. I just want to clarify one thing: at 8 PM in Mexico, the agreement we are discussing and the important contribution of the Slim Foundation will be announced; the authorities of the laboratory informed me today that they have chosen mAbxience to carry out this project due to the technological development that this company has. They do not do it specifically in their own factories or laboratories because they do not produce vaccines here, and they have told us that they are already ready to begin the process of technological transfer so that Argentina can start the production process as soon as possible once the final process of the last phase of the vaccine is completed. It is good news, it is a great expectation, it is a hopeful fact, and it is a great pride that we can work together with Mexico to provide a response for our beloved continent.

JOURNALIST.- When the vaccine is available, which is estimated to be in the first half of 2021, will there be any priority for certain sectors of the population in our country, any at-risk group that needs to be vaccinated first, and will it be included in the vaccination schedule, will it be mandatory for all Argentines?

GONZÁLEZ GARCÍA.- Yes, of course, as with all vaccines, there are priorities and protected groups; in that sense, clearly, the elderly will be prioritized, as well as health workers and those with any pre-existing conditions that make them more vulnerable. That is how we will start, as with all vaccinations, and then we will see how far it extends because, as with other vaccines, how far we will reach in immunity will be determined by the evolution of the pandemic itself, which we believe will take a significant hit with this, it will not eliminate it, but it will have a very strong impact on this evolution.

JOURNALIST.- I wanted to ask if both Argentina and Mexico will take the lead in the distribution of the vaccine to the rest of the countries; what mechanisms will be in place to ensure equitable distribution, and secondly, will this vaccine have a cost for the Argentine citizen, or has the decision already been made for the Argentine State to absorb the investment to vaccinate the population? And does having a deadline, a more concrete horizon for having a vaccine, change anything regarding the priorities or the work being done on isolation measures and the openings that were planned?

PRESIDENT.- That’s a lot of questions. First, this is a private venture of a laboratory called AstraZeneca, with the University of Oxford, which has received financial support from the Slim Foundation and has turned this project into a non-profit project. And this is very important to highlight, and we must celebrate the conduct of the company and the conduct of the University of Oxford because what they are guaranteeing is a vaccine without profit, without seeking profitability, without seeking economic benefits from that vaccine. This makes the vaccine particularly cheap compared to other projects we know, and we celebrate that. Let us keep in mind that the owners of the vaccine are AstraZeneca and the University of Oxford, and they are the ones guaranteeing equitable distribution; they have entrusted Argentina with the production of the central material of the vaccine and have entrusted Mexico with the final development, packaging, and distribution according to what the company decides.

This is a great relief for the future; it is not a solution for the present; in the present, we still have the same problems we are seeing, and unfortunately, what is shown is that the number of infections is rising and the number of deaths is increasing. At this point in time, this depends essentially on citizen behavior, on social behavior because we all see that practically activity has been largely liberated; it amazes me that I am still being talked to about quarantine because people are going out, taking care with masks, some are respecting social distancing, businesses are open, and commercial activity in Buenos Aires City is very broad today, as well as in Greater Buenos Aires. Therefore, there is a significant dose of social responsibility to be able to curb the number of infections and also the number of deaths.

As I always do, much to the chagrin of some, I call for reflection from society and for all of us to be clear that the risk is there, that the virus has not gone away, that the problem is not over, and that we all need to contribute our share of responsibility. For that, what we need to do is the same as always: maintain hygiene, wash our hands, use alcohol, wear masks, keep a safe distance, and avoid social gatherings, which is when people relax the most and infections thrive. The vaccine is not solving this problem today; the vaccine will be a very important solution for later. I insist, we are able to access the vaccine thanks to these agreements, 6 to 12 months earlier than we could access it without these agreements, and we have the privilege that the central material of the vaccine is produced by Argentine laboratories and in Argentina. But the truth is that in the present, it does not change anything for us, so we must be as rigorous as possible and as sensible as possible when analyzing the risks and the problem in its true dimension.

JOURNALIST.- I would like to ask for some clarifications regarding this very important announcement. First, why do you think Argentina was chosen to carry out this vaccine production? What are Argentina's capabilities in terms of science or private laboratories to carry out this production that will benefit Latin America along with Mexico? And secondly, did the authorities, the executives of the company you met with today provide any specifics on how much production they need to do, if there is a forecast of a certain quantity from a certain date to another date, how much Argentina would need to buy? I suppose these are details that will start to be designed now or perhaps are already decided.

PRESIDENT.- The first point: the reason why they chose mAbxience, which is a decision of the company, as they explained to me, is the technological development of the company, which practically allows it to transfer the technology without having to change or alter anything within the production capacity and deployment of production that the mAbxience laboratory has. The reason is that they found a laboratory in Argentina with the capacity and attitude to carry out this production. They have announced to us that they expect to carry out a production with a floor of 150 million doses and a ceiling of 250 million doses, calculating that Latin America will need around 230 million doses. Let us keep in mind that when I speak of Latin America, Brazil is excluded; it is excluded not for a commercial decision but because Brazil has another agreement with another development for the vaccine. Therefore, between 150 and 205 million doses is what is expected to be produced in Latin America. Argentina, we will make a more careful estimate, but it is clear that the first thing we will require is the number of doses necessary to preserve the health of at-risk individuals, our elderly and those who, due to some prevalent disease, are at greater risk of contagion. And then try to vaccinate all those who need vaccination because they have not been infected so far.

JOURNALIST.- What analysis do you make regarding the behavior of the Argentine population concerning the virus?

PRESIDENT.- They usually get angry with me when I make this analysis, but the truth is that I try to be very honest and very precise. So far, no one tells me that there is a better solution than to protect oneself, and what I see is that the number of cases is increasing because circulation is increasing, because the precautions that we constantly ask for do not exist, and what I would like is for everyone to see what happens to us when the virus enters and becomes difficult to contain. Days ago, in these last days, I have spoken several times with him; I spoke with the governor of Jujuy. Jujuy was more than a hundred days without any cases, and suddenly today it has 93 percent of its healthcare capacity occupied due to the level of contagion and the expansion that contagion has had. We must understand that circulation is a huge risk, that social gatherings are a huge risk; that the central problem we have is that we cannot know who is infected because there are many people who are infected and have no symptoms, and obviously, those people feel fine, do not feel at risk, and therefore feel that they are not putting the person next to them at risk, but they are. And so far, medical science has not found another solution than to isolate oneself. I understand that we would like to live in another time and under different conditions, but this is the time we have been given, and the truth is that discussing the solution that doctors propose is something I do not want to do. I call everyone's attention once again, and I ask you again, knowing that we have been facing the pandemic for many days, to please understand the risk we are running, and that the risk is the same in the City of Buenos Aires and in Greater Buenos Aires; it is not different. Greater Buenos Aires has more cases simply because it has many more inhabitants. But the risk is exactly the same. Therefore, I call upon you once again to exercise the prudence of taking care of yourselves; if each of us takes care of ourselves, we will be taking care of others.

JOURNALIST.- You just mentioned the importance of taking care of ourselves and maintaining isolation. In that sense, what is your opinion on the statements of some opposition figures that the Government has become bogged down in the quarantine or that in other countries there are freedoms? And in that context, what is your opinion on the call being made for next week by opposition sectors?

PRESIDENT.- I simply believe that they are mistaken, that they are not measuring things adequately. I would tell the opposition to talk to opposition figures like the governor of Jujuy and ask him what has happened to him, and note that the Governor made a lot of effort to prevent this from happening, and not everything depends on the effort that each of us can make. After that, each one must bear the responsibility that corresponds to them for calling for this type of thing. Freedom is not in question; health is in question. No freedom has been affected here; we are simply discussing the only way that science provides us to preserve our health in the face of the pandemic, that is all. After that, each one must take responsibility and bear the responsibility that corresponds to them; history will tell the responsibility that each one had. We have the peace of mind that we have always thought about the health of the people, that we have always tried to preserve health and life.

JOURNALIST.- You spoke about the first half of next year and said that three months before, vaccination could begin in our country. Are you estimating that vaccination will start in March? This is one question. The second question I wanted to ask relates to whether there are currently negotiation bridges with other countries that are also developing vaccines, such as Russia. I know you sent a letter to Putin; I don't know if you talked about the issue or referred to whether there are negotiations to also produce those vaccines that are being developed in other parts of the world.

PRESIDENT.- We are absolutely open to anyone who can provide us with a solution, and therefore we are willing. Today, when I wrote to President Putin to congratulate him on having found a vaccine or the path to finding a vaccine, I reminded him of what I raised at the G20, which was the need to socialize the technology that allows us to reach the vaccine. The transgenic vaccine project with the University of Oxford has almost that condition; they offer us the technology for us to develop it ourselves, and it is also a non-profit project, which are two very important aspects that deserve to be highlighted. It is a project that is also a little more advanced than others, and the initial results are very, very promising. Now, what we want is for Argentines to be able to immunize themselves against the risk of contagion as soon as possible. We celebrate and thank AstraZeneca and the University of Oxford for having found a place in Argentina to develop the vaccine, but whoever brings the vaccine first will be very welcome. In truth, the laboratory informs us that they estimate that in the first half we will be in a position to vaccinate. I also told you that Argentina had been selected because the chosen laboratory has technological conditions that allow for the quicker development of the vaccine, and they were already starting; they were making the final agreements. I spoke with Hugo Sigman, who is the head of the Argentine laboratory, and he conveyed to us that they are already starting the procedures to make that technology transfer. The sooner we have the vaccine, the better it will be. Believe me, the effort and work of the minister and his entire team have been enormous in trying to find a response, and we will continue working to find that response. In Mexico, it will be finished producing and will be packaged, and we will have the possibility of accessing the vaccine at the same time as the rest of Latin America. Thank you very much to all, good night.